Skip to content

Clinical Study of Intramuscular Spectinomycin for Mycoplasma genitalium Infection

A Study on the Efficacy and Safety of Intramuscular Spectinomycin for Refractory Mycoplasma genitalium Infections

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
JPRN
Registry ID
JPRN-jRCT1051250053
Enrollment
Unknown
Registered
2025-06-23
Start date
2025-06-23
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mycoplasma genitalium Infection

Interventions

None listed

Sponsors

Takashi Hirayama
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: "1. Those for whom satisfactory improvement effects were not observed with standard therapy. 2. Individuals who do not wish to undergo treatment with drugs commonly used in standard therapy due to concerns about side effects, and have been deemed suitable for treatment with conditioned medium by a physician. The patient selection criteria are as follows: Patients meeting the following criteria will be considered eligible: 1. Individuals aged 18 and above. 2. Individuals with normal decision-making capacity. 3. Individuals who have been provided with the informed consent document regarding this treatment, received sufficient explanation, and can provide voluntary written consent. 4. Individuals for whom the attending physician has recognized the necessity of treatment."

Exclusion criteria

Exclusion criteria: Exclusion Criteria: Participants will be excluded if they meet any of the following conditions: Users of narcotics or stimulants. Individuals deemed unsuitable by the attending physician.

Design outcomes

Primary

MeasureTime frame
MG/TVPCR

Secondary

MeasureTime frame
subjective symptoms, etc.

Contacts

Public ContactTakashi Hirayama

OSAKA UMEDA SHINSHI CLINIC

hirayama@gents-clinic.com+81-6-6373-0404

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026